SecSonar.com

AbbVie Inc. (ABBV)

AbbVie Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

AbbVie Inc. (ABBV) is a Drug Manufacturers - General company based in US with a market capitalization of $382B. Revenue grew 8.6% year-over-year and the company generated $17.8B in free cash flow. This page tracks ABBV's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 55K employees · IPO Jan 2, 2013

Valuation

Valuation & price

$210.82 · as of May 15, 2026 · -19.2% vs 52w high

88.5

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$261$223$185Jul 25Dec 25Jul 26Jul 7, 25$187.63Jul 9, 25$190.62Jul 11, 25$192.45Jul 15, 25$186.39Jul 17, 25$191.40Jul 21, 25$184.85Jul 23, 25$190.55Jul 25, 25$190.28Jul 29, 25$191.22Jul 31, 25$189.02Aug 4, 25$197.19Aug 6, 25$196.30Aug 11, 25$198.70Aug 13, 25$201.47Aug 15, 25$206.69Aug 19, 25$206.19Aug 21, 25$209.50Aug 25, 25$207.55Aug 27, 25$208.06Aug 29, 25$210.40Sep 3, 25$211.86Sep 5, 25$212.56Sep 9, 25$210.42Sep 11, 25$220.22Sep 16, 25$216.26Sep 18, 25$221.99Sep 22, 25$222.59Sep 24, 25$219.99Sep 26, 25$220.61Sep 30, 25$231.54Oct 2, 25$236.56Oct 6, 25$230.19Oct 8, 25$231.24Oct 10, 25$230.50Oct 14, 25$229.13Oct 16, 25$226.87Oct 21, 25$231.39Oct 23, 25$228.25Oct 27, 25$228.03Oct 29, 25$225.14Oct 31, 25$218.04Nov 4, 25$215.89Nov 6, 25$219.04Nov 10, 25$218.71Nov 12, 25$233.23Nov 14, 25$232.36Nov 18, 25$233.87Nov 20, 25$229.45Nov 25, 25$231.80Nov 28, 25$227.70Dec 2, 25$224.37Dec 4, 25$228.71Dec 8, 25$223.12Dec 10, 25$225.18Dec 12, 25$223.32Dec 16, 25$223.67Dec 18, 25$222.82Dec 22, 25$227.91Dec 24, 25$229.89Dec 29, 25$230.89Jan 2, 26$229.31Jan 6, 26$223.93Jan 8, 26$224.13Jan 12, 26$220.04Jan 14, 26$221.89Jan 16, 26$214.35Jan 21, 26$216.15Jan 23, 26$219.26Jan 27, 26$223.93Jan 29, 26$220.43Feb 2, 26$225.64Feb 4, 26$217.11Feb 9, 26$223.26Feb 11, 26$220.81Feb 13, 26$231.50Feb 18, 26$228.72Feb 20, 26$224.81Feb 24, 26$228.44Feb 26, 26$224.69Mar 2, 26$234.26Mar 4, 26$236.19Mar 6, 26$230.11Mar 10, 26$227.01Mar 12, 26$225.37Mar 17, 26$219.76Mar 19, 26$206.23Mar 23, 26$204.93Mar 25, 26$207.18Mar 27, 26$209.40Mar 31, 26$217.49Apr 2, 26$208.84Apr 7, 26$206.37Apr 9, 26$212.40Apr 13, 26$206.47Apr 15, 26$208.42Apr 17, 26$208.38Apr 22, 26$200.50Apr 24, 26$198.71Apr 28, 26$197.69Apr 30, 26$211.32May 4, 26$208.16May 6, 26$205.03May 8, 26$201.55May 12, 26$207.86May 14, 26$210.77May 18, 26$209.41May 20, 26$212.30May 22, 26$215.70May 28, 26$218.63Jun 1, 26$212.93Jun 3, 26$217.13Jun 5, 26$227.23Jun 9, 26$225.42Jun 11, 26$224.77Jun 15, 26$221.59Jun 17, 26$221.23Jun 22, 26$230.01Jun 24, 26$234.89Jun 26, 26$253.35Jul 2, 26$261.07
$184.8552-week range$261.07
Loading valuation history…

Fundamentals

Key fundamentals

$382B

Market cap

8.6%

Revenue growth (YoY)

70.2%

Gross margin

$17.8B

Free cash flow (USD)

$63.8B

Net debt

0.6%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$25.6BFY 2017$28.2BFY 2018$32.8BFY 2019$33.3BFY 2020$45.8BFY 2021$56.2BFY 2022$58.1BFY 2023$54.3BFY 2024$56.3BFY 2025$61.2B
$25.6B$61.2B

Free cash flow by year

2016 → 2025

FY 2016$6.6BFY 2017$9.4BFY 2018$12.8BFY 2019$12.8BFY 2020$16.8BFY 2021$22.0BFY 2022$24.2BFY 2023$22.1BFY 2024$17.8BFY 2025$17.8B
$6.6B$17.8B

Gross margin by year

2021 → 2025

FY 202169.0%FY 202270.0%FY 202362.4%FY 202470.0%FY 202570.2%
69.0%70.2%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 8, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAcquisition AnnouncedJun 22, 2026Filing
  • 8-K eventAnnual Meeting ResultsMay 12, 2026Filing
  • Quarterly report10-Q FiledMay 8, 2026Filing
  • 8-K eventEarnings ReleaseApr 29, 2026Filing
  • 8-K eventEarnings Guidance UpdateApr 3, 2026Filing

Questions

Frequently asked questions

What is AbbVie Inc.'s market cap?

AbbVie Inc. (ABBV) has a market capitalization of $382B.

What is ABBV's P/E ratio?

ABBV trades at a price-to-earnings ratio of 88.5, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

Are insiders buying ABBV stock?

SEC Form 4 filings show no open-market insider buys at AbbVie Inc. in the last 90 days (0 sells).

Same arena

Related companies in Drug Manufacturers - General

MRK

Merck & Co., Inc.

$293.4B

AZN

AstraZeneca PLC

$288.5B

NVS

Novartis AG

$287.1B

JNJ

Johnson & Johnson

$542.9B

AMGN

Amgen Inc.

$180.9B

GILD

Gilead Sciences, Inc.

$167.4B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.